✦ LIBER ✦

Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung

✍ Scribed by Suehisa, H.; Toyooka, S.; Hotta, K.; Uchida, A.; Soh, J.; Fujiwara, Y.; Matsuo, K.; Ouchida, M.; Takata, M.; Kiura, K.; Date, H.

Book ID: 118025573
Publisher: American Society of Clinical Oncology
Year: 2007
Tongue: English
Weight: 128 KB
Volume: 25
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2007.11.8646

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung

✍ Tomoya Fukui; Koji Tsuta; Koh Furuta; Shun-ichi Watanabe; Hisao Asamura; Yuichir 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 979 KB

Outcomes of Malaysian patients with adva

Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib

✍ Chong-Kin LIAM; Muventhiran RUTHRANESAN; Chee-Hong LEE; Yong-Kek PANG; Keong-Tio 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Adjuvant chemotherapy with uracil–tegafu

Adjuvant chemotherapy with uracil–tegafur prolongs overall survival in people with primary adenocarcinoma of the lung: Abstracted from: Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–21.

✍ WK (Bill) Evans 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Afatinib for patients with lung adenocar

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

✍ James Chih-Hsin Yang; Jin-Yuan Shih; Wu-Chou Su; Te-Chun Hsia; Chun-Ming Tsai; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 301 KB

Association Between Estrogen Receptor- E

Association Between Estrogen Receptor- Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung

✍ Nose, N.; Sugio, K.; Oyama, T.; Nozoe, T.; Uramoto, H.; Iwata, T.; Onitsuka, T.; 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 681 KB

Cost-effectiveness of epidermal growth f

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven